Lymphoma is an umbrella term describing dozens of cancers that begin in the immune system. Lymphomas are the most common type of blood cancer, broadly categorized as either Hodgkin or non-Hodgkin disease. All lymphoma subtypes combined are the seventh most common cancer in the United States.
Getting treated for lymphoma at City of Hope gives you access to unparalleled treatment options and exceptional care from experts in all subtypes of the disease, from rare and unusual to complex and chronic. It means you are the focus of a team of world-class scientific leaders who know the newest and best treatments for your disease — and likely played a role in their discovery.
This year, over 80,000 adults and children in the United States will be diagnosed with non-Hodgkin lymphoma and approximately 8,500 with Hodgkin lymphoma, according to the American Cancer Society.
About 90% of people with lymphoma are diagnosed with non-Hodgkin lymphoma.
Usually, there are no early warning signs of lymphoma, so diagnosis tends to occur during later stages. In addition, some of the first signs of lymphoma are the same as other illnesses, including swollen lymph nodes, cough and fever, making it challenging to diagnose early on.
City of Hope’s approach to treating lymphoma starts with a coordinated, multidisciplinary care team whose primary goals are helping you to live a long, healthy life free from cancer.
The newest therapies and treatment combinations, tailored to your specific type of lymphoma, are what guide your treatment. Our lymphoma specialists offer leading-edge therapies — and specialize in treating difficult lymphomas, including aggressive and slow-growing kinds.
Getting treated for lymphoma at City of Hope means you are steps away from labs developing new cancer treatments every day.
That proximity means you benefit from something unique in cancer care — “bench-to-bedside” treatment. For example, we test promising therapies and combinations manufactured in our campus labs on patients at lifesaving speed.
City of Hope's lymphoma program is among the best in the United States. We treat the full spectrum of disease — whether you are newly diagnosed or have cancer that has returned or failed to respond to previous therapies.
Our commitment to providing exceptional lymphoma care includes:
Expertise in rare lymphoma subtypes, like cutaneous T cell, double-hit B cell and AIDS-related lymphomas
Promising gene, vaccine and CAR T cell therapies, and combined immunotherapy with radiation therapy to boost the immune system's cancer-fighting response
A pioneering blood and bone marrow program that performs hundreds of transplants yearly and utilizes innovative approaches like pairing transplantation with new therapies
Advanced, focused radiation therapy techniques, including helical TomoTherapy used to direct radiation directly into bone marrow compartments, reducing recovery time and side effects
Genetic testing and customized drug therapy tailored to the molecular profile of specific lymphoma types
Collaboration with an international network of institutions, providing patients speedy access to the best therapies and latest clinical trials
Experience with difficult-to-treat groups, like older and pediatric patients and those with other chronic conditions
Survivorship clinics that support and monitor patients throughout the disease
Industry-leading supportive care programs to address disease-related financial, spiritual and symptoms issues
City of Hope is one of the few facilities designated a comprehensive cancer center by the National Cancer Institute.
Assistant Professor, Department of Hematology & Hematopoietic Cell Transplantation
A lymphoma expert, Niloufer Khan, M.D., came to City of Hope to work with a world-class, multidisciplinary team, including dermatologists and radiation oncologists, to treat patients with lymphoma, particularly T cell, Hodgkin and cutaneous lymphomas.
Swetha Kambhampati, M.D., sees her calling as a physician as the perfect way to combine her love for science with her passion for service. She aims to provide compassionate care tailored to each patient's needs. As an oncologist/hematologist specializing in lymphoma, she has experience and expertise
Steven T. Rosen, M.D., is a professor, Division of Lymphoma, Department of Hematology & Hematopoietic Cell Transplantation, and executive vice president and director emeritus, Comprehensive Cancer Center and Beckman Research Institute of City of Hope.